Evaluation of vaginal Misoprostol Effect on pregnancy Rate after IUI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206191306N5

Enrollment

210

Registered

2012-10-15

Start date

2012-09-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, childbirth and the puerperium. Sequelae of complication of pregnancy, childbirth and the puerperium

Interventions

Prescription of 200 microgram of Vaginal Misoprostol to intervention group

Prescription of Vaginal Placebo to control group

Intervention 1: Prescription of 200 microgram of Vaginal Misoprostol to intervention group. Intervention 2: Prescription of Vaginal Placebo to control group.

Treatment - Drugs

Placebo

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: patient with infertilitie's etioligy: 1-Male Factor, 2-Onovulatory Factor, that not yet fertile, despite use of Induction Ovulation and production Dominant follicule, 3-Idiopathic infertility, 4-The other reasons such as problems in Intercourse. The exclusion criteria: Other reasons of infertility

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pregnancy rate. Timepoint: 2 weeks after IUI. Method of measurement: Pregnancy test.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026